Loading
Nanoparticle-based Drug Delivery · Journal article
Frontiers in Chemistry · September 10, 2026
Encouraging direction, but not yet definitive.
In HER2-positive SKBR3 spheroids, DOX-ACA-HEX-G8 conjugate matched free doxorubicin potency (IC₅₀ <0.5 µM at 72 h) while reducing acute toxicity to cardiomyocytes (AC16) 18-fold and to normal epithelium (HB2) 15-fold, creating a 90-percentage-point separation in viability at matched dose. The effect is linker-dependent and does not extend to triple-negative models, and the mechanism of uptake and metabolic hormesis remains undefined.
In vitro comparative study using three-dimensional spheroid culture and cell viability assays. Human cardiomyocytes (AC16), non-tumorigenic mammary epithelium (HB2), HER2-positive breast cancer (SKBR3), and triple-negative breast cancer (MDA-MB-231) cell lines.. Intervention: DOX-ACA-HEX-G8 (doxorubicin conjugated to eight-guanidinium peptidomimetic H-O2Oc-[Dap(GO2)]8-O2Oc-NH2 via hexynoyl linker) and DOX-ACA-DBCO-G8 (same peptidomimetic via dibenzocyclooctyne linker).. Compared with: Free doxorubicin (DOX) and DOX-ACA-DBCO-G8 (to assess linker-dependent effect)..
DOX-ACA-HEX-G8 achieved SKBR3 IC₅₀ <0.5 µM (matched to free DOX) while reducing AC16 toxicity >18-fold and HB2 toxicity 15-fold At 0.5 µM/72 h, free DOX left SKBR3 at 6% and AC16 at 14% viability (8-point separation); DOX-ACA-HEX-G8 left SKBR3 at 32% and AC16 at 122% viability (90-point separation) DOX-ACA-DBCO-G8 (SPAAC linker) was less selective than DOX-ACA-HEX-G8 (CuAAC linker), showing effect is linker-dependent
No in vivo or animal data; acute 24–72 h spheroid exposure does not model cumulative cardiotoxicity or chronic dosing DOX-ACA-HEX-G8 achieved SKBR3 IC₅₀ <0.5 µM (matched to free DOX) while reducing AC16 toxicity >18-fold and HB2 toxicity 15-fold
DOX-ACA-HEX-G8 represents a promising chemical lead for reducing anthracycline cardiotoxicity in HER2-positive breast cancer. However, acute in vitro activity does not predict in vivo safety, efficacy, or pharmacokinetics; further studies of drug release kinetics, cellular uptake, and animal models are essential before clinical consideration.
A sound single-centre in vitro study showing a real conjugate chemistry result—reduced cardiomyocyte toxicity with retained HER2+ cancer activity—but limited to spheroid models, surrogate endpoints, and acute exposure without clinical translation or mechanistic validation.
As stated by the source record.
Quoted from the source exactly as published.
DOX-ACA-HEX-G8 represents a promising chemical lead for reducing anthracycline cardiotoxicity in HER2-positive breast cancer. However, acute in vitro activity does not predict in vivo safety, efficacy, or pharmacokinetics; further studies of drug release kinetics, cellular uptake, and animal models are essential before clinical consideration.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Doxorubicin (DOX) is a cornerstone anthracycline in breast cancer therapy, but its use is constrained by cumulative cardiotoxicity. We asked whether conjugation to a guanidinium-rich cell-penetrating peptidomimetic widens the window between anticancer activity and cardiomyocyte toxicity, or merely rescales potency. DOX was linked by azide–alkyne click chemistry to an eight-guanidinium peptidomimetic, H-O2Oc-[Dap(GO 2 )] 8 -O2Oc-NH 2, through either a hexynoyl linker (CuAAC; DOX-ACA-HEX-G8) or a dibenzocyclooctyne linker (SPAAC; DOX-ACA-DBCO-G8), so that the pair differs in a single variable. Both conjugates and free DOX were tested in three-dimensional spheroids of HER2-positive SKBR3, triple-negative MDA-MB-231, non-tumorigenic mammary epithelium (HB2) and human AC16 cardiomyocytes (0.5–50 μM; 24, 48 and 72 h; CellTiter-Glo 3D), and in a three-read-out control panel (LDH, ATP, DNA). Free DOX was potent but non-selective, killing SKBR3, HB2 and AC16 with comparable 72 h IC 50 values (<0.5, 0.78 and <0.5 µM) and leaving no meaningful window. DOX-ACA-HEX-G8 matched DOX against SKBR3 at 48–72 h (IC 50 < 0.5 µM) while being 15-fold (HB2) and >18-fold (AC16) less toxic to the non-malignant lines. Because the SKBR3 IC 50 is censored for both DOX and DOX-ACA-HEX-G8, their selectivity indices cannot be compared; the window is therefore established directly at matched concentration, without extrapolation: at 0.5 µM/72 h free DOX left SKBR3 at 6% and AC16 at 14% of control (an 8-percentage-point separation), whereas DOX-ACA-HEX-G8 left SKBR3 at 32% and AC16 at 122% (90 percentage points). The linker-matched DOX-ACA-DBCO-G8 was less selective, showing the effect tracks with linker chemistry. In the triple-negative model, DOX-ACA-HEX-G8 gave no window at all, and DOX-ACA-DBCO-G8 only a marginal one (selectivity index 1.6 for AC16 and 2.3 for HB2, both versus MDA-MB-231), although both conjugates were internalized. Both produced a pronounced low-dose hormetic signal in the non-malignant lines; a cell-free spike-recovery control excluded an artifact of the luminescence read-out, and the biomass read-out excluded proliferation, so the effect is metabolic and its mechanism remains open. DOX-ACA-HEX-G8 is a lead for anthracycline delivery with reduced acute cardiomyocyte toxicity, contingent on mechanistic studies of uptake and drug release.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.